Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel PGD(2) receptor expressed in eosinophils.

William S Powell1

  • 1Meakins-Christie Laboratories, McGill University, 3626 St Urbain Street, Montreal, Quebec, Canada H2X 2P2. william.powell@mcgill.ca

Prostaglandins, Leukotrienes, and Essential Fatty Acids
|August 5, 2003
PubMed
Summary

Prostaglandin D2 (PGD2) acts through the DP2 receptor to promote eosinophil activity, suggesting its role as a key inflammatory mediator in asthma. This highlights PGD2

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concise Syntheses of Microsomal Metabolites of a Potent OXE (Oxoeicosanoid) Receptor Antagonist.

Chemical & pharmaceutical bulletin·2023
Same author

Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2022
Same author

Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates.

British journal of pharmacology·2021
Same author

Eicosanoid receptors as therapeutic targets for asthma.

Clinical science (London, England : 1979)·2021
Same author

Protein kinase C activates NAD kinase in human neutrophils.

Free radical biology & medicine·2020
Same author

Targeting the OXE receptor as a potential novel therapy for asthma.

Biochemical pharmacology·2020

Area of Science:

  • Immunology
  • Biochemistry
  • Pharmacology

Background:

  • Prostaglandin D2 (PGD2), a product of arachidonic acid metabolism by mast cells, is released in the lungs during allergen challenges.
  • The classic PGD2 receptor (DP receptor) mediates effects like smooth muscle relaxation and inhibition of platelet aggregation.
  • A second PGD2 receptor, DP2 (chemoattractant receptor-homologous molecule expressed on Th2 cells), has been identified.

Purpose of the Study:

  • To investigate the role of PGD2 and its DP2 receptor in allergic inflammation, particularly in asthma.
  • To characterize the signaling pathways and cellular responses mediated by DP2 receptor activation.

Main Methods:

  • Utilized potent DP2 receptor agonists, including 15R-methyl-PGD2 and 15-deoxy-Delta(12,14)-PGJ2.
  • Assessed DP2 receptor-mediated effects such as eosinophil chemotaxis, actin polymerization, and calcium mobilization.

Main Results:

  • PGD2, acting via the DP2 receptor, induces significant eosinophil chemotaxis, actin polymerization, calcium mobilization, and adhesion molecule expression.
  • 15R-methyl-PGD2 is identified as a highly potent DP2 receptor agonist.
  • 15-Deoxy-Delta(12,14)-PGJ2 activates eosinophils at low concentrations, preceding its anti-inflammatory effects.

Conclusions:

  • PGD2's potent effects on eosinophils, coupled with its presence in the lung, suggest it is a critical proinflammatory mediator in asthma.
  • The DP2 receptor is a key target for understanding and potentially treating allergic airway inflammation.

Related Experiment Videos